Innovation Pharmaceuticals Inc (IPIX)

[biodoc]

I agree. It's amazing that there's any impact on tumor with once a week/ 3x per month dosing for a drug with a two hour half life. Over the weekend I was taking a closer look at all the information presented so far for Kevetrin/ovarian ca and also noticed eight patients with ovarian ca on the ASCO poster. I considered the Mullerian serous adeno as possibly the ninth. It doesn't seem likely. Maybe the ovarian ca patient who dropped out was considered in the nine but not on the ASCO poster? Not sure about discontinuing after a cohort vs. dropout. Insights appreciated.

edit: iclight- just read your subsequent posts. On my way to work in a few.